Trials / Completed
CompletedNCT04182373
KW-3357 Study in Patients With Early Onset Severe Preeclampsia
A Phase 3, Randomized, Placebo-controlled, Double Blind Study of KW-3357 in Patients With Early Onset Severe Preeclampsia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 181 (actual)
- Sponsor
- Kyowa Kirin Co., Ltd. · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy of intravenous KW-3357 in patients with early-onset severe preeclampsia by comparing the prolongation days of pregnancy with that of placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Antithrombin gamma | Intravenous infusion, once a day, 7 days |
| DRUG | physiological saline | Intravenous infusion, once a day, 7 days |
Timeline
- Start date
- 2019-11-19
- Primary completion
- 2023-05-17
- Completion
- 2023-06-16
- First posted
- 2019-12-02
- Last updated
- 2023-11-15
Locations
63 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT04182373. Inclusion in this directory is not an endorsement.